Remdesivir improves biomarkers associated with disease severity in COVID-19 patients treated in an outpatient setting.

Overall, the findings in this study suggest that RDV treatment may accelerate the improvement of multiple biomarkers of COVID-19 severity, which are associated with better clinical outcomes during infection. These findings have implications for better understanding the activity of antiviral treatments in COVID-19.